Sponsors Fail To Win US FDA Endorsement For Trimming Trials During Pandemic
Agency more interested in switching to remote methods or imputing data than reducing sample size or duration of cell/gene therapy trials, official tells ASGCT.
You may also be interested in...
Agency acknowledged burden regulations for implementing GMP provisions of FD&C Act placed on API manufacturers in regulatory burden notice.
International association of pharmaceutical inspectorates launches industry consultation on aligning with the one EU GMP provision it spurned years ago.
Two batches were authorized because they were made before production waste jammed Emergent BioSolutions' Bayview plant.